Citi Downgrades Bio-Techne to Neutral, Cites Valuation
Citi: Bio-Techne (TECH.US) rating downgraded from buying to neutral, with a target price of $85.00.
Bio-Techne Analyst Ratings
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
Analysts' Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept
Bio-Techne Analyst Ratings
Baird Maintains Outperform on Bio-Techne, Raises Price Target to $81
KeyBanc Remains a Buy on Bio-Techne (TECH)
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82
RBC Capital Sticks to Its Hold Rating for Bio-Techne (TECH)
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79
Navigating 4 Analyst Ratings For Bio-Techne
Deutsche Bank: Maintaining the Bio-Techne (TECH.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $85.00 to $82.00.
Bio-Techne Analyst Ratings
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating
Bio-Techne: Solid Consumables Business and Strategic Investments Anchor Buy Rating Amid Sector Headwinds
No Data